UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000030453 |
|---|---|
| Receipt number | R000034771 |
| Scientific Title | Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia |
| Date of disclosure of the study information | 2017/12/18 |
| Last modified on | 2022/06/22 09:10:20 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia
Acronym
Aplastic anemia 01 study in West Japan Hematology Study Group (W-JHS AA01 study)
Scientific Title
Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia
Scientific Title:Acronym
Aplastic anemia 01 study in West Japan Hematology Study Group (W-JHS AA01 study)
Region
| Japan |
Condition
Condition
aplastic anemia
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
We prospectively determine the efficacy of cyclosporine (CsA) in the treatment of non-severe aplastic anemia which does not require blood transfusions.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Hematologic improvement in the erythrocyte (HI-E) and platelet (HI-P) count according to IWG response criteria 2006 at 8 weeks after CsA therapy.
Key secondary outcomes
1.Increment of reticulocyte >=20,000/mm3 at 8 weeks after the initiation of CsA.
2.HI-E or HI-P at 4 weeks, 16 weeks and 52 weeks after the initiation of CsA.
3.Increment of reticulocyte >=20,000/mm3 at 4 weeks, 16 weeks and 52 weeks after the initiation of CsA.
4.Correlation between HI-E or HI-P at 8 weeks after the initiation of CsA and the following biomarkers; presence of increased PNH-type cells, presence of cells with HLA class I allele-lacking leukocytes, and plasma thrombopoietin.
5.Correlation between HI-E or HI-P at 8 weeks after the initiation of CsA and somatic gene mutations.
6.Time to HI-E or HI-P after the initiation of CsA.
7.Incidence of somatic mutations in granulocyts.
8.Adverse events >=grade 3 associated with CsA therapy.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
1. Start CsA (Neoral or generic drugs emulsified in the same way as Neoral) at a dose of 3.5 mg/kg, bid (before breakfast and before dinner).
2. Measure the blood concentration of cyclosporine at 2 hours (C2) after taking the drug and determine the minimum dose of cyclosporine that produces C2 >600 ng/mL. Continue the dose of cyclosporine for 8 weeks.
3. Continue the treatment for further 44 weeks (a total of 52 weeks) when patients meet the response criteria of HI-E or HI-P at the end of the 8 week treatment. Treatments after the 52 weeks are not specified. When patients do not meet the IWG response criteria 2006 at the end of 8 weeks, the treatment is terminated and treatments after 9 weeks are not specified.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 16 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Aged >=16 years.
2) Good PS (0, 1 and 2)
3) Meet the diagnostic criteria of aplastic anemia of stage 1 or 2, and is planned to receive CsA as a first treatment.
4) Meet both of the platelet count < 100,000/mm3 and the reticulocyte count < 60,000/ mm3, and at least one of the followings; hemoglobin level <10.0 g/dL and the neutrophil count < 1,500/ mm3.
5) The percentage of cellular component in a bone marrow biopsy specimen is <30%.
6) No treatment history with anti-thymocyte globulin (ATG), CsA, anabolic steroid, erythropoietin preparation, eltrombopag and vitamin K.
7) Not pregnant, or agree to contraception during the study period.
Key exclusion criteria
1) Disease duration >=5 years. Patients whose disease onset is unclear are not excluded.
2) Severe (stage 3 or 4) or moderately severe (stage 3) aplastic anemia that is defined by the severity criteria by the Ministry of Health, Welfare, and Labor of Japan.
3) Patients with chromosomal abnormalities related to MDS that were defined by WHO 2008 diagnostic criteria.
4) Patients showing dysplastic signs defined as category A morphological abnormalities (1. hypo-segmented mature neutrophils (pseudo-Pelger nuclear abnormality), 2. degranulation of neutrophils, 3. micromegakaryocytes, 4. ringed sideroblasts) in "Atlas on diagnosis accuracy division and morphological diagnosis based on morphologic dysplasia of refractory anemia (myelodysplastic syndromes) ".
5) Congenital aplastic anemia including Fanconi anemia.
6) Patients who developed a cancer or received chemotherapy or radiotherapy within 5 years of entry.
7) Patients with uncontrollable infections.
8) Patients with severe impairment of the liver, heart or kidney (eGFR < 45 mL/min/1.73m2).
9) Patients who were judged to be ineligible for the study participation by investigators.
Target sample size
33
Research contact person
Name of lead principal investigator
| 1st name | Shinji |
| Middle name | |
| Last name | Nakao |
Organization
Kanazawa University Hospital
Division name
Department of Hematology
Zip code
920-8641
Address
13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
TEL
076-265-2000(ext2273)
snakao8205@staff.kanazawa-u.ac.jp
Public contact
Name of contact person
| 1st name | Ken |
| Middle name | |
| Last name | Ishiyama |
Organization
Kanazawa University Hospital
Division name
Department of Hematology
Zip code
920-8641
Address
13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
TEL
076-265-2000(ext2273)
Homepage URL
ishiyama-knz@umin.ac.jp
Sponsor or person
Institute
Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kanazawa University Hospital
Address
13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
Tel
076-265-2049
crc.irb-knz@esct.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 12 | Month | 18 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
34
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2017 | Year | 12 | Month | 14 | Day |
Date of IRB
| 2017 | Year | 12 | Month | 19 | Day |
Anticipated trial start date
| 2017 | Year | 12 | Month | 20 | Day |
Last follow-up date
| 2021 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 12 | Month | 18 | Day |
Last modified on
| 2022 | Year | 06 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034771
